Cash Flow Statement (Annual)

BSFT / BroadSoft, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016
Net Cash Provided By Used In Operating Activities
  Net Income Loss -7,849 7,992 32,297 12,076 -8,874 1,012 179 816
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation And Amortization - 1,300 1,800 2,600 3,900 7,000 9,800 11,400
    Amortization Of Software Licenses 1,820 1,820 1,820 2,910 2,987 3,342 2,848 3,401
    Share Based Compensation 3,629 3,008 7,201 15,022 41,684 29,628 40,444 51,507
    Provision For Doubtful Accounts 59 3 -56 644 149 274 4 313
    Deferred Income Taxes And Tax Credits - 7 5 5,088 -7,058 -3,548 -2,741 -2,031
    Paid In Kind Interest - - 2,560 5,120 5,504 5,906 8,617 12,684
  Increase Decrease In Operating Capital
    Increase Decrease In Accounts Receivable 4,147 15,023 5,997 2,557 16,334 14,806 23,935 12,499
    Increase Decrease In Other Operating Assets 1,004 463 511 16,414 1,128 4,056 4,896 7,606
    Increase Decrease In Accounts Payable And Accrued Liabilities -3,532 630 238 -1,125 -1,799 4,655 2,234 4,815
    Increase Decrease In Deferred Revenue 18,869 19,217 -3,240 4,013 16,473 22,911 9,099 -2,000
  Net Cash Provided By Used In Operating Activities 10,427 19,386 28,575 30,598 31,934 54,759 44,786 67,097
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Property Plant And Equipment 769 2,630 2,421 3,923 5,789 10,523 12,876 15,738
  Payments To Acquire Businesses Net Of Cash Acquired -806 2,191 16,748 25,177 37,793 3,650 21,172 34,678
  Payments To Acquire Marketable Securities - 18,673 137,305 179,886 117,067 122,991 252,467 281,111
  Proceeds From Sale Of Available For Sale Securities - - 11,267 3,000 0 10,000 128,827 106,355
  Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities - - 46,962 171,458 103,240 109,042 69,677 69,085
  Net Cash Provided By Used In Investing Activities 694 -24,274 -99,136 -34,153 -57,406 -17,558 -88,011 -156,087
Net Cash Provided By Used In Financing Activities
  Proceeds From Stock Options Exercised 69 762 3,943 2,459 1,285 710 6,187 15,181
  Taxes Paid On Vesting Of Rsus - 525 574 2,198 2,977 7,795 10,297 17,944
  Net Cash Provided By Used In Financing Activities -2,684 29,203 117,431 -121 4,831 -4,135 118,918 -2,467
Effect Of Exchange Rate On Cash And Cash Equivalents 79 70 -52 149 -38 -1,389 -1,379 -1,407
Cash And Cash Equivalents Period Increase Decrease 8,516 24,385 46,818 -3,527 -20,679 31,677 74,314 -92,864
Cash And Cash Equivalents At Carrying Value - - 94,072 90,545 69,866 101,543 175,857 82,993

Peers - Prepackaged Software (7372)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 11133B409